[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 47 of about 47
1. Mangili G, De Marzi P, Beatrice S, Rabaiotti E, Viganò R, Frigerio L, Gentile C, Fazio F: Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings. BMC Cancer; 2006;6:198
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings.
  • BACKGROUND: There is still much debate about the best adjuvant therapy after surgery for endometrial cancer (EC) and there are no current guidelines.
  • METHODS: Twenty-three patients with high-risk EC (stage IIB, IIIA, IIIC or IC G3 without lymphadenectomy or with aneuploid tumor) underwent primary surgery and were then referred for adjuvant therapy.
  • P was given at a dose of 60 mg/m2 once weekly for five weeks during RT, which consisted of a total radiation dose of 50.4 Gy.
  • Overall survival and disease-free survival were calculated from the time of surgery.
  • RESULTS: A total of 157 cycles of P were administered both during radiotherapy and consolidation chemotherapy.
  • Median time to recurrence was 18.6 months (range 3-28).
  • In this group median time to recurrence was 19.2 months (range 3-28).
  • CONCLUSION: This small series demonstrates pelvic radiotherapy in combination with weakly P followed by three consolidation chemotherapy cycles as an effective combined approach in high risk endometrial carcinoma patients.
  • [MeSH-major] Chemotherapy, Adjuvant / methods. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / radiotherapy. Paclitaxel / therapeutic use. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Aged. Disease-Free Survival. Female. Humans. Middle Aged. Pilot Projects. Ploidies. Radiation Dosage. Recurrence. Risk Factors. Treatment Failure

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Radiat Oncol. 2000 Jan;10(1):23-8 [10671655.001]
  • [Cites] Cell Motil Cytoskeleton. 2000 Mar;45(3):223-34 [10706777.001]
  • [Cites] Lancet. 2000 Apr 22;355(9213):1404-11 [10791524.001]
  • [Cites] Gynecol Obstet Invest. 2000;50(2):127-32 [10965198.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):53-7 [11277649.001]
  • [Cites] J Epidemiol Biostat. 2001;6(1):47-86 [11385776.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1145-53 [11483323.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4048-53 [11600606.001]
  • [Cites] J Reprod Med. 2002 Mar;47(3):173-89; discussion 189-90 [11933681.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(3):216-20 [12094958.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):537-46 [13678721.001]
  • [Cites] Cancer Invest. 2003;21(6):887-96 [14735693.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6D):5191-6 [14981988.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73 [15093913.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):345-52 [15099944.001]
  • [Cites] Histopathology. 2004 Jun;44(6):603-14 [15186276.001]
  • [Cites] Cancer Treat Rep. 1979 Jan;63(1):21-7 [369691.001]
  • [Cites] Obstet Gynecol. 1980 Oct;56(4):419-27 [6999399.001]
  • [Cites] Obstet Gynecol. 1982 Feb;59(2):225-8 [7043339.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):166-71 [2298404.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):305-8 [2227540.001]
  • [Cites] Gynecol Oncol. 1991 Jan;40(1):55-65 [1989916.001]
  • [Cites] Am J Obstet Gynecol. 1994 Jun;170(6):1677-81; discussion 1681-2 [8203425.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2682-6 [7989944.001]
  • [Cites] Gynecol Oncol. 1995 May;57(2):138-44 [7729725.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1996 Jan;48(1):45-51 [8576621.001]
  • [Cites] Anticancer Drugs. 1996 Feb;7(2):182-8 [8740723.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] Clin Obstet Gynecol. 1996 Sep;39(3):716-27 [8862895.001]
  • [Cites] Gynecol Oncol. 1996 Oct;63(1):34-9 [8898165.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):861-3 [8922203.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6 Suppl 16):108-12 [9007135.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):885-95 [9128966.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • [Cites] Am J Clin Oncol. 1996 Jun;19(3):290-1 [8638543.001]
  • (PMID = 16869961.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC1559635
  •  go-up   go-down


2. Kim S, Wu HG, Lee HP, Kang SB, Song YS, Park NH, Ha SW: Patterns of failure after postoperative radiation therapy for endometrial carcinoma. Cancer Res Treat; 2006;38(3):133-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure after postoperative radiation therapy for endometrial carcinoma.
  • PURPOSE: We tried to investigate the outcome and patterns of failure of endometrial cancer patients who were treated with surgery and postoperative radiation therapy (RT).
  • MATERIALS AND METHODS: Eighty-three patients with endometrial cancer who received postoperative RT between May 1979 and August 2000 were included in this retrospective study.
  • All the patients were staged according to 1988 FIGO (International Federation of Gynecology and Obstetrics) staging system; 2 were stage IA, 23 were stage IB, 20 were stage IC, 4 were stage IIA, 5 were stage IIB, 9 were stage IIIA, 2 were stage IIIB and 18 were stage IIIC.
  • RESULTS: Overall, 11 patients (13%) experienced disease relapse: 4 with initial stage I or II disease and 7 with initial stage III disease.
  • Among the 54 stage I or II patients, 1 (2%) relapsed in the pelvis only, 2 (4%) relapsed in the vagina and distant organs, and 1 (2%) relapsed in the paraaortic lymph nodes (PANs).
  • Among the 29 stage III patients, 1 (3%) relapsed in the vagina.
  • The most common sites of failure for the stage III patients were the peritoneum (3 patients, 10%), PANs (2 patients, 7%), and lung (2 patients, 7%).
  • The five-year DFS rate was 93%, 100% and 74% for the stage I, II and III patients, respectively.
  • Three patients experienced severe radiation-related late complications: RTOG (Radiation Therapy Oncology Group) grade 3 radiation cystitis was seen in one patient, and grade 3 bowel obstruction was seen in two patients.
  • The major patterns of failure for stage III patients were peritoneal seeding and distant metastasis.
  • Selective use of whole abdominal radiotherapy or adjuvant chemotherapy may improve the therapeutic outcome of these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):233-8 [11161865.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):79-85 [11006036.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):834-8 [15927414.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):101-4 [9747826.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] Gynecol Oncol. 1995 May;57(2):138-44 [7729725.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1992 Nov;4(6):373-6 [1463690.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):905-11 [1555983.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):68-70 [2703169.001]
  • [Cites] J Natl Cancer Inst. 1988 Apr 20;80(4):276-8 [3280811.001]
  • [Cites] Radiobiol Radiother (Berl). 1987;28(4):519-28 [3685293.001]
  • [Cites] Obstet Gynecol. 1980 Oct;56(4):419-27 [6999399.001]
  • [Cites] Cancer Treat Rep. 1979 Jan;63(1):21-7 [369691.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73 [15093913.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):236-42 [12713986.001]
  • [Cites] Gynecol Oncol. 2002 Dec;87(3):274-80 [12468325.001]
  • [Cites] Gynecol Oncol. 2002 Mar;84(3):437-42 [11855884.001]
  • (PMID = 19771273.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2741680
  • [Keywords] NOTNLM ; Endometrial neoplasms / Patterns of failure / Postoperative radiation therapy
  •  go-up   go-down


3. Izaki H, Takahashi M, Shiirevnyamba A, Taue R, Furumoto H, Bando Y, Murakami Y, Fukawa T, Koizumi T, Yamamoto Y, Yamaguchi K, Nakatsuji H, Kishimoto T, Fukumori T, Kanayama HO: Long-term recurrence-free survivor after laparoscopic removal of solitary adrenal metastasis from endometrial adenocarcinoma. J Med Invest; 2010 Feb;57(1-2):174-7
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term recurrence-free survivor after laparoscopic removal of solitary adrenal metastasis from endometrial adenocarcinoma.
  • Solitary adrenal metastasis from endometrial adenocarcinoma is extremely rare.
  • We report herein the case of a laparoscopically resected solitary adrenal metastasis originating from endometrial adenocarcinoma.
  • The patient was a 55-year-old woman who had undergone total abdominal hysterectomy for stage IIIc endometrial carcinoma, followed by 7 courses of adjuvant chemotherapy comprising carboplatin and paclitaxel.
  • However, the patient developed an isolated right adrenal metastasis 15 months postoperatively.
  • To the best of our knowledge, this is the first case of solitary adrenal metastasis originating from endometrial adenocarcinoma that is controlled for the long term by successful laparoscopic resection.
  • [MeSH-major] Adenocarcinoma / pathology. Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Endometrial Neoplasms / pathology. Laparoscopy
  • [MeSH-minor] Female. Humans. Middle Aged. Survivors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20299759.001).
  • [ISSN] 1349-6867
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Havrilesky LJ, Cragun JM, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A: Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol; 2005 Dec;99(3):689-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of lymph node metastases influences survival in stage IIIC endometrial cancer.
  • OBJECTIVE: Surgical staging of endometrial cancer identifies those patients with microscopic metastatic disease most likely to benefit from adjuvant therapy and may also confer therapeutic benefit.
  • Our objective was to compare survival of patients who underwent resection of grossly positive lymph nodes (LN) to those with microscopically positive LN.
  • METHODS: Patients had stage IIIC endometrial cancer with pelvic and/or aortic LN metastases and underwent surgery between 1973 and 2002.
  • Exclusion criteria included pre-surgical radiation and second primary cancer.
  • RESULTS: Mean age of 96 patients with stage IIIC endometrial cancer was 64.
  • There were 45 cases with microscopic LN involvement and 51 with grossly enlarged LN.
  • Overall, 41% had disease in aortic LN, which in 18% represented isolated aortic LN metastasis.
  • Adjuvant therapies were given to 92% of patients (85% radiotherapy, 10% chemotherapy, 10% progestins).
  • Among those with grossly involved LN, 86% were completely resected.
  • Five-year disease-specific survival (DSS) was 63% in 45 patients with microscopic metastatic disease compared to 50% in 44 patients with grossly positive LN completely resected and 43% in 7 with residual macroscopic disease.
  • In multivariable analyses, gross nodal disease not debulked (HR=6.85, P=0.009), serosal/adnexal involvement (HR=2.24, P=0.036), diagnosis prior to 1989 (HR=4.33, P<0.001), older age (HR=1.09, P<0.001), and >2 positive lymph nodes (HR=3.12, P=0.007) were associated with lower DSS.
  • CONCLUSION: Grossly involved LN can often be completely resected in patients with stage IIIC endometrial cancer.
  • These retrospective data provide evidence suggestive of a therapeutic benefit for lymphadenectomy in endometrial cancer.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Lymph Nodes / pathology. Lymph Nodes / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16126261.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Hétu V, Petignat P, Wu Y, Drouin P, Sauthier P, Provencher D, Gauthier P: Positive adnexal or uterine serosal involvement in stage IIIC endometrial cancer is an adverse factor for recurrence. Gynecol Obstet Invest; 2009;67(3):173-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive adnexal or uterine serosal involvement in stage IIIC endometrial cancer is an adverse factor for recurrence.
  • OBJECTIVES: Clinical and pathological significance of stage IIIC endometrial cancer is unclear.
  • Our study was designed to determine the risk of recurrence among patients with stage IIIC endometrial cancer according to different pathological findings.
  • METHODS: We retrospectively reviewed all patients with FIGO IIIC endometrial carcinoma (n = 48) treated in our institution between 1996 and 2005.
  • Patients were classified into two groups: with adnexae and/or uterine serosal metastasis (group A, n = 18) and without metastasis (group B, n = 20).
  • Eighteen patients received adjuvant chemotherapy and pelvic radiotherapy, 17 received pelvic radiotherapy alone, and 11 received chemotherapy or hormonotherapy.
  • Serosal and/or adnexal involvement was a negative independent prognostic factor for disease-free survival [relative risk = 3.75 (1.01-13.9); p = 0.04], whereas histological type, grade, depth of invasion and age at diagnosis had no influence.
  • CONCLUSION: Patients with stage IIIC endometrial cancer and metastasis to adnexae and/or serosa have a higher risk of recurrence than those with node metastasis alone.
  • Optimal adjuvant therapy for these groups remains unclear.
  • [MeSH-major] Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local. Ovarian Neoplasms / secondary. Peritoneum / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 19088481.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Katz LA, Andrews SJ, Fanning J: Survival after multimodality treatment for stage IIIC endometrial cancer. Am J Obstet Gynecol; 2001 May;184(6):1071-3
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after multimodality treatment for stage IIIC endometrial cancer.
  • OBJECTIVE: Our purpose was to review our results of multimodality treatment of lymph node metastasis in endometrial cancer (stage IIIC).
  • STUDY DESIGN: All patients underwent surgical staging for endometrial cancer with complete pelvic and aortic lymphadenectomy.
  • Patients with microscopic nodal metastasis received adjuvant teletherapy, whereas those with macroscopic nodal metastasis received chemotherapy (carboplatin AUC 5 and paclitaxel 135 mg/m2 every 3 weeks for 6 courses) followed by teletherapy.
  • RESULTS: Twenty-one patients had stage IIIC disease, and one had stage IVB (inguinal nodal metastasis).
  • At a median follow-up of 3.8 years, 32% of patients had recurrence, all extrapelvic.
  • CONCLUSION: Our surgical, chemotherapeutic, and radiation treatment protocol for stage IIIC endometrial cancer produced minimal toxicity and good survival.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11349160.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Matsuo K, Bond VK, Eno ML, Im DD, Rosenshein NB: Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. Int J Cancer; 2009 Dec 1;125(11):2721-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
  • The objective of this study was to evaluate the role of an in vitro drug resistance assay to platinum and taxane in the management of advanced epithelial ovarian, fallopian and primary peritoneal cancer.
  • All patients with FIGO Stage IIIc and IV who received postoperative chemotherapy with platinum and taxane for more than 4 courses after the initial cytoreductive surgery between 1995 and 2008 were evaluated.
  • Patients who received neoadjuvant chemotherapy were not included.
  • An in vitro drug resistance assay (EDR Assay, Oncotech, Tustin, CA) was used to determine drug resistance for each patient's tumor tissue.
  • Level of drug resistance was described as extreme (EDR), intermediate (IDR), or low (LDR).
  • Response to chemotherapy and survival were correlated to the EDR Assay.
  • In conclusion, LDR to both platinum and taxane chemotherapy, as determined by an in vitro drug resistance assay, independently predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer, especially in those patients who undergo optimal primary cytoreduction.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biological Assay / methods. Drug Resistance, Neoplasm. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / secondary. Bridged Compounds / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / mortality. Endometrial Neoplasms / secondary. Female. Humans. In Vitro Techniques. Lymphatic Metastasis. Middle Aged. Organoplatinum Compounds / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Taxoids / administration & dosage


8. McMeekin DS, Lashbrook D, Gold M, Johnson G, Walker JL, Mannel R: Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol; 2001 May;81(2):273-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of FIGO Stage IIIc endometrial cancer patients.
  • OBJECTIVE: The aim of this study was to analyze FIGO Stage IIIc endometrial cancer (EC) patients to better define clinicopathologic associations, patterns of failure, and survival.
  • Data on clinicopathologic variables, adjuvant treatment, site of first recurrence, and survival were collected.
  • RESULTS: From 607 EC patients evaluated, 47 (8%) were identified with FIGO Stage IIIc disease.
  • Stage IIIc disease was defined by positive PLN alone in 38%, positive PLN and PALN in 41%, and positive PALN alone in 17%.
  • Nearly 1/3 of cases had papillary serous or clear cell histology.
  • Postoperative adjuvant treatment included whole abdominal radiation (36%), pelvic radiation with (19%) and without (17%) extended field, chemotherapy (17%), and oral progestins (11%).
  • The 3-year and 5-year survival estimates for all patients were 77 and 65%, respectively.
  • Consideration of substaging Stage IIIc patients based on positive adnexa or cytology is supported by the data.
  • The extent which adjuvant treatments contributed to the 77% 3-year survival remains to be defined.
  • The patterns of failure suggest a possible role for combined modalities in future treatments.
  • [MeSH-major] Endometrial Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Survival Analysis. Treatment Failure

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11330962.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Matsuura M, Suzuki T, Morishita M, Tanaka R, Ito E, Saito T: Chemotherapy (CT) with radiotherapy versus CT alone for FIGO Stage IIIc endometrial cancer. Eur J Gynaecol Oncol; 2009;30(1):40-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy (CT) with radiotherapy versus CT alone for FIGO Stage IIIc endometrial cancer.
  • To determine optimal treatment for women with Stage IIIc endometrial carcinoma, extended-field radiotherapy (RT) plus chemotherapy (CT) was compared versus CT alone as adjuvant therapy.
  • Twenty-nine patients with FIGO Stage IIIc endometrial cancer who underwent adjuvant treatment with 4.4 courses of CT (CAP or TC/DC) or 4.5 courses of CT (CAP or TC/DC) plus external pelvic RT (50 Gy) with paraaortic boost after surgery between 1992 and 2004 were retrospectively assessed.
  • Fifteen patients underwent CT alone and 14 received combined treatment with CT/RT.
  • Following treatment, the recurrence rate was 46.6% and 28.5% in the two treatment arms, respectively.
  • Combined treatment with RT/CT was associated with a better survival rate than CT alone (78% versus 62%, respectively).
  • In Stage IIIc endometrial cancer, combined treatment with RT and CT reduces pelvic recurrence and improves progression-free survival and overall survival compared with CT alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / radiotherapy. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Female. Humans. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317255.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Fujimoto T, Nanjyo H, Nakamura A, Yokoyama Y, Takano T, Shoji T, Nakahara K, Yamada H, Mizunuma H, Yaegashi N, Sugiyama T, Kurachi H, Sato A, Tanaka T: Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer. Gynecol Oncol; 2007 Nov;107(2):253-9
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer.
  • OBJECTIVE: The purpose of this study was to determine whether para-aortic lymphadenectomy improves disease-related survival (DRS) in stage IIIc endometrial cancer.
  • METHODS: A total of 63 patients with stage IIIc endometrial carcinoma underwent primary radical surgery in the Tohoku Gynecologic Cancer Unit from 1993 to 2004.
  • All patients had modified radical hysterectomy, bilateral salpingo-oophorectomy, systemic pelvic lymph node (PLN) adenectomy, and with or without para-aortic lymph node (PAN) adenectomy, followed by adjuvant chemotherapy.
  • CONCLUSIONS: The number of positive PLN site is an independent prognostic factor in stage IIIc endometrial cancer.
  • A large prospective clinical trial needs to be conducted to establish the strategy of PAN adenectomy before or intra-operative treatment.
  • [MeSH-major] Endometrial Neoplasms / mortality. Endometrial Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / pathology. Lymph Nodes / surgery
  • [MeSH-minor] Aged. Aorta. Disease-Free Survival. Female. Humans. Japan / epidemiology. Kaplan-Meier Estimate. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pelvis. Prognosis. Proportional Hazards Models. Retroperitoneal Space. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640720.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Ivanov SI: [Modern tendencies in treatment of endometrial cancer stage III C]. Akush Ginekol (Sofiia); 2008;47(3):29-31
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Modern tendencies in treatment of endometrial cancer stage III C].
  • OBJECTIVE: The aim of our research work was to evaluate the potential of treatment in patients with endometrial cancer stage IIIC, with positive enlarged lymph nodes.
  • MATERIAL AND METHODS: 102 patients with endometrial cancer stage IIIC were researched for the period of 1990 till 2008.
  • In 30 patients--postoperative paraaortal radiotherapy, and 25 patients was applied postoperative chemotherapy.
  • In multivariation analysis, the independent prognostic factors were: the size of the lymph node, the residual tumour/metastatic lymph nodes/--p < 0,001, the age < 65 years--p = 0,001, and the implementation of adjuvant chemotherapy/p = 0,016/.
  • CONCLUSIONS: In patients with endometrial cancer stage IIIC, the resection/debulking/ of macroscopic enlarged lymph nodes and the implementation of adjuvant chemotherapy in addition to radiotherapy is connected with better survival rate.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18756829.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


12. Bristow RE, Zahurak ML, Alexander CJ, Zellars RC, Montz FJ: FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer; 2003 Sep-Oct;13(5):664-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival.
  • The objective of this study was to evaluate the potential survival benefit of debulking macroscopic adenopathy and other clinical prognostic factors among patients with node-positive endometrial carcinoma.
  • Demographic, operative, pathologic, and follow-up data were abstracted retrospectively for 41 eligible patients with FIGO stage IIIC endometrial cancer.
  • Postoperatively, all patients received whole pelvic radiation therapy, 17 received extended-field radiation therapy, and 15 patients received chemotherapy.
  • The median disease-specific survival (DSS) time for all patients was 30.6 months (median follow-up 34. 0 months).
  • Patients with completely resected macroscopic lymphadenopathy had a significantly longer median DSS time (37.5 months), compared to patients left with gross residual nodal disease (8.8 months, P = 0.006).
  • 001), age > or = 65 years (HR 6.22, 95% CI 2.05-18.87, P = 0.001), and the administration of adjuvant chemotherapy (HR 0.22, 95% CI 0.07-0.76, P = 0.016).
  • We conclude that in patients with stage IIIC endometrial carcinoma, complete resection of macroscopic nodal disease and the administration of adjuvant chemotherapy, in addition to directed radiation therapy, are associated with improved survival.
  • [MeSH-major] Endometrial Neoplasms / mortality. Endometrial Neoplasms / surgery. Lymph Nodes / surgery. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Aorta, Thoracic. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Combined Modality Therapy. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Disease-Free Survival. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Maryland / epidemiology. Middle Aged. Neoplasm Staging. Pelvis. Proportional Hazards Models. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14675352.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Cohn DE, Resnick KE, Ramirez NC, Morrison CD: Advanced endometrial cancer with serous metastasis in a 17-year-old. Gynecol Oncol; 2006 May;101(2):356-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced endometrial cancer with serous metastasis in a 17-year-old.
  • BACKGROUND: Endometrial cancers with a component of serous histology generally occur in postmenopausal women and can present with advanced disease even in the absence of a deeply myoinvasive primary malignancy.
  • We present a case of stage IIIC endometrial cancer with serous histology in a 17-year-old.
  • CASE: A 17-year-old presented with menorrhagia requiring blood transfusion and a transvaginal ultrasound demonstrated a 31 mm endometrial stripe within a bulky uterus.
  • Endometrial curettage revealed a grade 2 endometrioid adenocarcinoma.
  • The patient desired definitive surgical management for her disease; a stage IIIC endometrial cancer with focal low-grade serous carcinoma among a grade 2 endometrioid carcinoma was noted to be superficially myoinvasive.
  • Platinum-based chemotherapy was administered, and the patient is without disease 24 months following therapy.
  • CONCLUSION: Advanced endometrial cancer with metastasis of serous carcinoma to the retroperitoneal lymph nodes can occur, albeit extraordinarily rarely, in very young women.
  • This information is critically important when counseling a woman regarding conservative management of endometrial adenocarcinoma with the interest of preservation of her fertility.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499956.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Watari H, Todo Y, Takeda M, Ebina Y, Yamamoto R, Sakuragi N: Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer. Gynecol Oncol; 2005 Mar;96(3):651-7
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
  • OBJECTIVE: The aim of this study was to determine pathologic variables associated with disease-specific survival of node-positive patients with endometrial carcinoma treated with combination of surgery including pelvic and para-aortic lymphadenectomy and adjuvant chemotherapy.
  • METHODS: Survival of 55 node-positive endometrial carcinoma patients prospectively treated with surgery and adjuvant chemotherapy between 1982 and 2002 at Hokkaido University Hospital was compared to various histopathologic variables.
  • All patients underwent primary surgical treatment including pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy consisting of intravenous cisplatin, doxorubicin, and cyclophosphamide.
  • RESULTS: Among 303 consecutive endometrial cancer patients treated during the period of this study, 55 patients (18.2%), including 44 without peritoneal metastasis (FIGO stage IIIc) and 11 with peritoneal metastasis (FIGO stage IV), were found to have retroperitoneal lymph node metastasis.
  • Multivariate Cox regression analysis revealed that peritoneal metastasis and lymph-vascular space invasion (LVSI) were independently related to poor survival in node-positive endometrial carcinoma.
  • The estimated 5-year survival rate of stage IIIc patients with or without moderate/prominent LVSI was 50.9% and 93.3%, respectively with statistically significant difference (P=0.0024).
  • The estimated 5-year survival rate of stage IV patients was 20.0%.
  • Prognosis of stage IIIc patients could be stratified into three groups by the number of positive para-aortic node (PAN) with an estimated 5-year survival rate of 86.4% for no positive PAN (n = 23), 60.4% for one positive PAN (n = 13), and 20.0% for > or = 2 positive PAN (n = 8).
  • Survival of patients with stage IIIc disease could be stratified into three groups by combination of LVSI and number of positive PAN groups with an estimated 5-year survival rate of 93.3% for no or one positive PAN group with nil or minimal LVSI, 62.6% for no or one positive PAN group with intermediate or prominent LVSI, and 20.0% for > or = 2 positive PAN groups irrespective of LVSI (P = 0.0002 for no or one positive PAN group with nil or minimal LVSI vs > or = 2 positive PAN groups, P = 0.0223 for no or one positive PAN group with nil or minimal LVSI vs no or one positive PAN group with intermediate or prominent LVSI, P = 0.0388 for no or one positive PAN group with intermediate or prominent LVSI vs > or = 2 positive PAN groups).
  • CONCLUSIONS: LVSI and number of positive PAN groups were independent prognostic factors for stage IIIc endometrial cancer patients.
  • Postoperative therapy and follow-up modality need to be individualized according to LVSI and the number of positive PAN for stage IIIc patients.
  • New molecular markers to predict the prognosis of endometrial cancer patients preoperatively should be found for individualization of treatment.
  • New chemotherapy regimen including taxane needs to be considered as an adjuvant therapy for patients with node-positive endometrial cancer.
  • [MeSH-major] Endometrial Neoplasms / pathology. Lymph Nodes / pathology. Lymphatic Vessels / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Analysis

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721407.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Arenas Prat M, Rovirosa A, Sabater S, Ameijide A, Henríquez I, Servitja S, Cabezas I, Mur E, Gumà J: Experience with endometrial carcinoma (EC): A population-based study in Tarragona Province (Spain). J Clin Oncol; 2009 May 20;27(15_suppl):e16550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience with endometrial carcinoma (EC): A population-based study in Tarragona Province (Spain).
  • FIGO Stage (S): 8.2% IA; 36.2% IB; 19% IC; 7.8% IIA; 6.5% IIB; 7.3% IIIA; 1.3% IIIB; 3.4% IIIC; 2.6% IVA; 2.2 IVB.
  • TREATMENT:. 1) Surgery in 93.5%, 49.6% lymph nodes dissection.
  • 3) Chemotherapy in 11.1% and hormonal treatment in 6.9%. 3).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960813.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. du Bois A, Combe M, Rochon J, Jackisch C, Malaurie E, Lueck HJ, Loibl S, Schroeder W, Burges A, Weber B: Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB-IV. An AGO-GINECO Intergroup phase III trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):5007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB-IV. An AGO-GINECO Intergroup phase III trial.
  • : 5007 Background: The addition of further drugs to TC is regarded as an option for improving 1st-line therapy in OC.
  • Anthracyclines have shown activity in OC and are among the drugs suitable for evaluation in triple drug regimens.
  • METHODS: We performed a randomized phase III trial in pts. with advanced OC stages FIGO IIB-IV to determine the role of epirubicin (E) when added to TC.
  • Pts were randomized to receive 6 cycles of either T 175 mg/m<sup>2</sup> 3 h iv + C AUC 5 (according to Calvert formula) + E 60 mg/m<sup>2</sup> iv (TEC) or TC at same doses, both regimens given every 3 weeks. Pts. were stratified per center and according to FIGO stage and post-operative residual tumor (RT): stratum I 'FIGO IIB-IIIC and RT =/<1 cm'; stratum II 'FIGO IIB-IIIC and RT > 1 cm or FIGO IV'.
  • Exploratory post hoc subgroup analysis did not show differences with respect to residual tumor (0 vs 1-10 vs > 10 mm), but for histological subtypes; the latter suggested superior efficacy for TEC in endometrial OC.
  • Therefore, TEC cannot be recommended as first-line therapy of advanced OC in clinical routine.
  • Further research should focus on the role of anthracylines in endometrial OC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015491.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Watari H, Todo Y, Takeda M, Ebina Y, Yamamoto R, Sakuragi N: A multivariate analysis on histopathologic prognostic factors for predicting outcome of node-positive endometrial carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):5064

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multivariate analysis on histopathologic prognostic factors for predicting outcome of node-positive endometrial carcinoma.
  • : 5064 Background: Prognosis of advanced endometrial cancer patients (stage IIIc and IV) is poor.
  • In order to clarify the histopathologic prognostic factors of node-positive endometrial cancer, we performed the following analysis.
  • METHODS: A retrospective review of 55 node-positive endometrial cancer patients (44 in stage IIIc and 11 in stage IV) among 303 patients treated between 1982 and 2002 at Hokkaido University Hospital was performed.
  • All Patients underwent primary surgical treatment including pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy consisting of intravenous cisplatin, doxorubicin, and cyclophoshamide.
  • RESULTS: Multivariate analysis revealed that FIGO (1988) stage and lymph-vascular space invasion (LVSI) of the tumor were found to be independently related to poor survival .
  • The estimated 5-year survival rate of stage IIIc patients with or without moderate/prominent LVSI was 50.9 % and 93.3 %, respectively.
  • The estimated 5-year survival rate of stage IV patients was 20.0%.
  • In stage IIIc patients, multivariate analysis showed that LVSI alone was found to be an independent prognostic factor for survival.
  • Prognosis of stage IIIc patients could be stratified into three groups by the number of positive para-aortic lymph node (PAN) with an estimated 5-year survival rate of 86.4% for no positive PAN (n=23), 60.4% for 1 positive PAN (n=13), 20.0% for >=2 positive PAN (n=8).
  • CONCLUSIONS: LVSI was an independent prognostic factor for stage IIIc patients and their prognosis was stratified by the number of positive PAN.
  • Postoperative therapy and follow-up modality need to be individualized according to LVSI and the number of positive PAN for stage IIIc patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015573.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Bermudez Wagner KM, Thomas MB, Miyamoto C, Micaily B, Hernandez E: Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA). J Clin Oncol; 2009 May 20;27(15_suppl):e16511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA).
  • : e16511 Background: Pelvic lymph node dissection (LND) requirement to adequately stage endometrial cancer has been subject of debate.
  • We conducted an outcome analysis of clinical stage I endometrioid endometrial adenocarcinoma (EEA) patients who underwent surgery with tailored LND and adjuvant therapy (radiation (RT) or chemotherapy) between 1997 and 2008.
  • RESULTS: 119 patients (stage I 92, II 11, III 15, and IV 1) were identified.
  • The OS for stage I and IIIC was 88% and 83%, respectively.
  • CONCLUSIONS: In patients with EEA, a tailored approach to LND and adjuvant therapy results in good outcome, but many still have therapy-associated adverse events.
  • Although no difference was found in OS between patients who underwent LND and those who did not, similar survival for patients with stages I and IIIC suggests that therapy directed by the knowledge of nodal status may have an impact on survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960757.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Mariani A, Webb MJ, Keeney GL, Haddock MG, Aletti G, Podratz KC: Stage IIIC endometrioid corpus cancer includes distinct subgroups. Gynecol Oncol; 2002 Oct;87(1):112-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IIIC endometrioid corpus cancer includes distinct subgroups.
  • OBJECTIVE: Because stage IIIC corpus cancer is a heterogeneous substage, the outcomes of patients with stage IIIC disease were assessed according to the extent of extrauterine disease.
  • METHODS: From 1984 through 1993, 51 patients with surgical stage IIIC corpus cancer were treated at our institution; 5 patients had tumors with nonendometrioid histologic features and were excluded from the analyses.
  • Of the 46 patients with endometrioid carcinoma, 22 had lymph nodes as the only site of extrauterine disease (stage IIIC(0)) and 24 also had peritoneal cytologic, uterine serosal, adnexal, or vaginal involvement or a combination of these (stage IIIC(ab)).
  • RESULTS: Patients with stage IIIC(0) cancer had a 5-year cause-specific survival (CSS) of 72% and a 5-year recurrence-free survival (RFS) of 68%, and those with stage IIIC(ab) had a CSS of 33% and an RFS of 25% (P < 0.01).
  • Of the 22 patients with stage IIIC(0) endometrioid cancer, 21 had adjuvant radiotherapy (1 also received chemotherapy) and 1 was not treated.
  • Of the 24 patients with stage IIIC(ab) cancer, 16 received adjuvant radiotherapy (1 had concomitant chemotherapy), 2 had chemotherapy, 4 had hormonal therapy, and 2 were not treated.
  • CONCLUSION: Assessment of CSS, RFS, and sites of relapse suggests that FIGO surgical stage IIIC endometrioid corpus cancer includes two distinct and readily separable subgroups:.
  • (1) stage IIIC(0), nodal involvement only, and (2) stage IIIC(ab), nodal plus cytologic, uterine serosal, adnexal, or vaginal involvement, or a combination of these.
  • Our results also suggest that different treatment strategies are needed for these subgroups.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12468351.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Mundt AJ, Murphy KT, Rotmensch J, Waggoner SE, Yamada SD, Connell PP: Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1154-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma.
  • OBJECTIVE: To determine the outcome, pattern(s) of failure, and optimal treatment volume in Stage IIIC endometrial carcinoma patients treated with surgery and postoperative radiation therapy (RT).
  • METHODS: Between 1983 and 1998, 30 Stage IIIC endometrial carcinoma patients were treated with primary surgery and postoperative RT at the University of Chicago.
  • Adjuvant vaginal brachytherapy (VB) was delivered in 10, chemotherapy in 5, and hormonal therapy in 7 patients.
  • Patients treated with VB had a trend to a lower vaginal recurrence rate (0/10 vs. 4/20, p = 0.12) than those not receiving VB.
  • No patient developed an isolated abdominal recurrence.
  • Two patients developed significant RT sequelae: chronic diarrhea in 1 patient treated with WPRT and VB, and small bowel obstruction in 1 patient treated with EFRT.
  • CONCLUSION: FIGO Stage IIIC disease comprises a small percentage of endometrial carcinoma patients but carries a poor prognosis.
  • Given the predominance of failure in distant sites, attention should be focused on the development of systemic chemotherapy protocols.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy. Hysterectomy. Ovariectomy. Radiotherapy, Adjuvant
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Antineoplastic Agents, Hormonal / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Chicago / epidemiology. Combined Modality Therapy. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / radiotherapy. Cystadenocarcinoma, Papillary / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Life Tables. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483324.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


21. Frigerio L, Mangili G, Aletti G, Carnelli M, Garavaglia E, Beatrice S, Ferrari A: Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study. Gynecol Oncol; 2001 Apr;81(1):53-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study.
  • OBJECTIVE: Postoperative radiotherapy (RT) is the most used adjuvant treatment in high risk endometrial cancer (HREC), and it appears to reduce the incidence of pelvic relapses but doesn't seem to improve survival.
  • Paclitaxel (P) has shown in vitro and clinical activity against endometrial cancer, and it is also a potent radiosensitizer by blocking dividing cells in G2/M phase.
  • This is the first study that verifies the feasibility of a treatment with concomitant weekly chemotherapy and RT to potentially reduce the incidence of local and distant relapses in order to improve survival in HREC.
  • Four patients presented stage IC disease, 2 women had IIB stage tumors, 5 patients revealed IIIA stage disease, and 2 had stage IIIC.
  • /m(2)) via a continuous 1-h infusion once weekly during the 5 weeks of RT (mean radiation dose of 50.4 Gy).
  • One patient developed a subocclusion 8 weeks after the end of the treatment, with medical resolution.
  • No patients developed hypersensitivity reactions.
  • CONCLUSIONS: Concomitant P and RT is safe and acceptable treatment in patients with HREC.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / radiotherapy. Paclitaxel / adverse effects. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Diarrhea / chemically induced. Diarrhea / etiology. Drug Administration Schedule. Drug Eruptions / etiology. Feasibility Studies. Female. Hematologic Diseases / chemically induced. Hematologic Diseases / etiology. Humans. Middle Aged. Neoplasm Staging. Radiation Injuries / etiology. Radiodermatitis / etiology. Radiotherapy / adverse effects. Radiotherapy, Adjuvant. Risk Factors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11277649.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Radiation-Sensitizing Agents; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


22. Nishio S, Koyanagi T, Miyabe K, Kuromatsu H: [Two cases of multidrug-resistant recurrent endometrial cancer successfully treated with medroxyprogesterone acetate (MPA)]. Gan To Kagaku Ryoho; 2010 Apr;37(4):735-8
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of multidrug-resistant recurrent endometrial cancer successfully treated with medroxyprogesterone acetate (MPA)].
  • We report two cases of multidrug-resistant endometrial cancer which recurred after the initial therapy and progressed despite further anticancer chemotherapy, but could be successfully treated with medroxyprogesterone acetate (MPA).
  • The first patient with stage IVb moderately-differentiated endometrioid adenocarcinoma of the uterine corpus underwent initial operation and postoperative chemotherapy followed by maintenance chemotherapy.
  • The second patient with stage IIIc poorly-differentiated endometrioid adenocarcinoma of the uterine corpus developed lung metastases 14 months after the initial operation and postoperative chemotherapy.
  • Subsequent chemotherapy yielded a complete response(CR).
  • Two months later, however, a small intestinal metastasis was observed, which was treated by surgical excision and chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Endometrial Neoplasms / drug therapy. Medroxyprogesterone Acetate / therapeutic use
  • [MeSH-minor] Aged. Female. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Middle Aged. Neoplasm Staging. Recurrence. Remission Induction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414038.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


23. Lupe K, D'Souza DP, Kwon JS, Radwan JS, Harle IA, Hammond JA, Carey MS: Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer. Gynecol Oncol; 2009 Jul;114(1):94-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
  • OBJECTIVE: To evaluate recurrence and survival associated with adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
  • METHOD: This is a prospective cohort study of women with Stage III and IV endometrial cancer treated at a single institution between April 2002 and July 2006.
  • Adjuvant therapy consisted of 4 cycles of intravenous paclitaxel (175 mg/m(2)) and carboplatin (350 mg/m(2)) every 3 weeks, followed by external beam radiotherapy (RT) to the pelvis (45 Gy), then another 2 cycles of chemotherapy.
  • The majority had Stage IIIC disease (63%), and the most common histology was serous carcinoma (49%).
  • Six cycles of combination chemotherapy were completed in 81%, and all patients completed pelvic RT.
  • CONCLUSION: Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation is associated with a low rate of local recurrence and favorable survival for advanced endometrial cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant / methods. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Paclitaxel / administration & dosage


24. Watari H, Mitamura T, Moriwaki M, Hosaka M, Ohba Y, Sudo S, Todo Y, Takeda M, Ebina Y, Sakuragi N: Survival and failure pattern of patients with endometrial cancer after extensive surgery including systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy. Int J Gynecol Cancer; 2009 Dec;19(9):1585-90
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and failure pattern of patients with endometrial cancer after extensive surgery including systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy.
  • We investigated the survival and the failure pattern of 288 patients with endometrial cancer treated with extensive surgery including systematic pelvic and para-aortic lymphadenectomy followed by cisplatin-based chemotherapy from 1982 to 2002.
  • The 5-year overall survival rates were 97.5% for stage I, 87.5% for stage II, 85.2% for stage III, and 12.5% for stage IV.
  • Notably, the 5-year survival rate was 76.5% for patients with stage IIIC disease.
  • Among patients with a low risk (n = 92) for recurrence who received no adjuvant chemotherapy, 2 (2.2%) showed recurrent disease.
  • Among those with intermediate (n = 98) and high (n = 98) risks for recurrence who received adjuvant chemotherapy, 9 (9.2%) and 20 (20.4%) showed recurrent disease, respectively.
  • For patients with stage I/II cancer, the architectural and nuclear grades were related to distant failure.
  • We conclude that we need to further test the efficacy of systemic adjuvant therapy using new chemotherapeutic regimens to prevent distant failure and to improve the survival of patients with endometrial cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / surgery
  • [MeSH-minor] Aorta, Abdominal / surgery. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Gynecologic Surgical Procedures / methods. Humans. Lymph Node Excision. Pelvis / surgery. Recurrence. Retrospective Studies. Survival Analysis. Treatment Failure

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955942.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. Thomas L, Bataillard A, Brémond A, Fondrinier E, Fervers B, Achard JL, Lansac J, Bailly C, Hoffstetter S, Basuyau JP, d'Anjou J, Descamps P, Farsi F, Guastalla JP, Laffargue F, Rodier JF, Vincent P, Pigneux J: [Standards, options, and recommendations for the radiotherapy of patients with endometrial cancer. FNCLCC (National Federation of Cancer Campaign Centers) and CRLCC (Regional Cancer Campaign Centers)]. Cancer Radiother; 2001 Apr;5(2):163-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Standards, options, and recommendations for the radiotherapy of patients with endometrial cancer. FNCLCC (National Federation of Cancer Campaign Centers) and CRLCC (Regional Cancer Campaign Centers)].
  • [Transliterated title] Standards, Options et Recommandations pour la radiothérapie des patientes atteintes de cancer de l'endomètre.
  • OBJECTIVES: To develop clinical practice guidelines according to the definitions of the Standards, Options and Recommendations project for the radiotherapy of carcinoma of the endometrium.
  • Once the guidelines were defined, the document was submitted for review to independent reviewers, and to the medical committees of the 20 French Cancer Centres.
  • RESULTS: The main recommendations for the radiotherapy of carcinoma of the endometrium are:.
  • 1) For grade 1 and 2 stage IA tumours, follow-up alone is standard as additional treatment.
  • For grade 1 and 2 stage IB tumours, vaginal brachytherapy or follow-up alone are options.
  • For grade 3, stage IB tumours and stage IC disease, there are two treatment options: external pelvic radiotherapy with a brachytherapy boost or vaginal brachytherapy.
  • 2) Treatment for stage II disease can be preoperative when stage II disease has been suggested by a positive endometrial curettage.
  • Postoperative vaginal brachytherapy is given for stage IIA tumours if the penetration of the myometrium is less than 50% or if the tumour is grade 1 or 2.
  • In the case of deep penetration, or higher grade disease, or for stage IIB external radiotherapy with brachytherapy boosting must be undertaken routinely.
  • 3) After surgery, for stage IIIA disease, either external pelvic radiotherapy or abdomino-pelvic radiotherapy is indicated, along with medical treatment in certain patients.
  • For stage IIIB tumours, postoperative external radiotherapy with brachytherapy (if possible) should be undertaken.
  • For stage IIIC tumours, standard treatment is external (pelvic or pelvic and para-aortic) radiotherapy followed or not by a brachytherapy boost.
  • In case of extrauterine sites involved abdomino-pelvic irradiation is recommended.
  • 4) Standard treatment for inoperable stage I and II disease is external radiotherapy and brachytherapy.
  • For patients with inoperable stage III or IV disease, treatment is often symptomatic, combining external radiotherapy and medical treatment.
  • [MeSH-major] Endometrial Neoplasms / radiotherapy. Radiotherapy / standards
  • [MeSH-minor] Brachytherapy / adverse effects. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma / radiotherapy. Carcinoma / surgery. Cesium Radioisotopes / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Hysterectomy. Indium Radioisotopes / therapeutic use. Lymphatic Irradiation / adverse effects. Lymphatic Metastasis / radiotherapy. Neoplasm Staging. Pelvic Neoplasms / radiotherapy. Pelvic Neoplasms / secondary. Peritoneal Neoplasms / radiotherapy. Peritoneal Neoplasms / secondary. Postoperative Period. Preoperative Care. Radiation Injuries / etiology. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, High-Energy / adverse effects. Radium / therapeutic use

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11355582.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Guideline; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cesium Radioisotopes; 0 / Indium Radioisotopes; W90AYD6R3Q / Radium
  •  go-up   go-down


26. Lupe K, Kwon J, D'Souza D, Gawlik C, Stitt L, Whiston F, Nascu P, Wong E, Carey MS: Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach. Int J Radiat Oncol Biol Phys; 2007 Jan 1;67(1):110-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach.
  • PURPOSE: To determine the feasibility of adjuvant paclitaxel and carboplatin chemotherapy interposed with involved field radiotherapy for women with advanced endometrial cancer.
  • METHODS AND MATERIALS: This was a prospective cohort study of women with Stage III and IV endometrial cancer.
  • Adjuvant therapy consisted of 4 cycles of paclitaxel (175 mg/m(2)) and carboplatin (350 mg/m(2)) every 3 weeks, followed sequentially by external beam radiotherapy (RT) to the pelvis (45 Gy), followed by an additional two cycles of chemotherapy.
  • RESULTS: Thirty-three patients (median age, 63 years) received treatment between April 2002 and June 2005.
  • Stage distribution was as follows: IIIA (21%), IIIC (70%), IVB (9%).
  • Combination chemotherapy was successfully administered to 30 patients (91%) and 25 patients (76%), before and after RT respectively.
  • Nine patients (27%) experienced acute Grade 3 or 4 chemotherapy toxicities.
  • Six (18%) patients developed chronic RT toxicity.
  • There were no treatment-related deaths.
  • CONCLUSIONS: Adjuvant treatment with combination chemotherapy interposed with involved field radiation in advanced endometrial cancer was well tolerated.
  • This protocol may be suitable for further evaluation in a clinical trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carboplatin / adverse effects. Chemotherapy, Adjuvant / adverse effects. Drug Administration Schedule. Feasibility Studies. Female. Humans. Hysterectomy. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Prospective Studies. Radiation Injuries / etiology. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084542.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


27. Gocheva L, Slavchev B: Whole abdominal irradiation in endometrial cancer - a single institution study. J BUON; 2009 Oct-Dec;14(4):613-8
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole abdominal irradiation in endometrial cancer - a single institution study.
  • PURPOSE: To examine the use of whole abdominal irradiation (WAI) open field technique in patients with stage III endometrial cancer (EC).
  • METHODS: Between 1993 and 2007, 26 patients (age 39-70 years, median 58) with stage III EC (IIIA 15, IIIB 2, IIIC 8) were treated with WAI after primary surgery.
  • In 84% of the patients WAI consisted of 30 Gy, delivered mainly in daily fractions of 1.5 Gy (81%), 5 fractions per week.
  • For the remaining patients the dose was 25 Gy (8%) and 20 Gy (8%), respectively.
  • After abdominal RT, 85% of the patients were given a pelvic boost to reach 45 - 50 Gy with 1.8 Gy/fraction/day, using a Co 60 unit.
  • In 5 (19%) patients boost to 45-50 Gy with 1.8 Gy/fraction/day to other risk sites was also given.
  • Two (8%) of 26 patients received 2 cycles of platinum-based chemotherapy.
  • The mean follow-up time was 13.41 years.
  • RESULTS: The treatment time ranged from 14-74 days, median 48.
  • Ten (38.5%) patients received their treatment with no interruption, and in 16 (61.5%) patients RT was transiently interrupted because of acute gastrointestinal and hematological toxicity.
  • Neither grade 4 acute complications nor mortality while receiving treatment were observed.
  • Late side effects (grade 2 gastrointestinal complications) developed in 1 (5%) patient.
  • CONCLUSION: WAI achieves a quite favorable 5- and 14-year survival rate with an acceptable risk of acute and late side effects in properly selected patients with stage III EC.
  • WAI as a sole or a part of combined treatment warrants further investigation in patients with high-risk EC.
  • [MeSH-major] Abdomen / radiation effects. Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148451.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


28. Landrum LM, Moore KN, Myers TK, Lanneau GS Jr, McMeekin DS, Walker JL, Gold MA: Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. Gynecol Oncol; 2009 Feb;112(2):337-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
  • OBJECTIVE: The pattern of metastasis for Stage IV endometrial carcinoma (EC) is similar to that for ovarian carcinoma (OC), hence the goal of surgical management for both diseases is optimal cytoreduction (CRS) followed by adjuvant chemotherapy.
  • METHODS: Patients with Stage IVB EC treated with curative intent between the years of 1990-2006 were identified and data abstracted regarding demographics, surgical procedures, pathologic factors, and follow-up.
  • Two patients with Stage IIIC OC were matched for each Stage IVB EC based on age and residual disease.
  • Stage IVB EC patients with distant metastasis were excluded.
  • All OC patients underwent primary CRS and received combination platinum based chemotherapy.
  • RESULTS: 55 patients with Stage IVB EC underwent primary CRS and adjuvant therapy with curative intent.
  • Adjuvant therapy with curative intent included platinum based combination chemotherapy (60%, n=33), platinum based chemotherapy with radiation (25%, n=14), and radiation alone (15%, n=8) depending on the time period of treatment.
  • Seven patients had residual disease >1 cm following CRS, 6 of whom received chemotherapy alone.
  • CONCLUSIONS: The treatment paradigm for advanced EC has undergone a drastic evolution from palliation to CRS and combination chemotherapy.
  • Further research to identify the molecular characteristics of EC may identify important differences from OC and provide insight for the development of novel primary and salvage treatment strategies for patients with advanced EC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / therapy. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Chemotherapy, Adjuvant. Cohort Studies. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome


29. Nishimura N, Hachisuga T, Saito T, Kawarabayashi T: Subsequent endometrial carcinoma with adjuvant tamoxifen treatment in Japanese breast cancer patients. Int J Gynecol Cancer; 2001 Jul-Aug;11(4):272-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subsequent endometrial carcinoma with adjuvant tamoxifen treatment in Japanese breast cancer patients.
  • This study aimed to detail the clinicopathologic features of endometrial carcinomas that developed in Japanese patients receiving adjuvant tamoxifen treatment for breast cancer patients.
  • Ten endometrial carcinomas in tamoxifen-treated breast cancer patients were collected from two medical centers.
  • The endometrial carcinomas included two stage Ia, four stage Ib, two stage Ic and two stage IIIc.
  • The tumor was limited to the endometrium in two cases.
  • Deep cervical invasion was recognized in one case.
  • The cell types comprised nine endometrioid adenocarcinomas and one serous carcinoma.
  • Five of eight postmenopausal endometrial carcinomas were associated with polypoid endometrial lesions composed of cystically dilated atrophic and proliferative glands widely separated by fibrotic stroma.
  • Two patients with retroperitoneal lymph node metastases died of endometrial cancer.
  • One patient developed a contralateral breast cancer during tamoxifen treatment.
  • No patient died of breast cancer.
  • We did not demonstrate a higher frequency of either high-grade tumors or unfavorable histologic subtypes in tamoxifen-treated Japanese breast cancer patients.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Endometrial Neoplasms / etiology. Tamoxifen / adverse effects
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Aged. Asian Continental Ancestry Group. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / etiology. Cystadenocarcinoma, Serous / pathology. Female. Humans. Japan. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11520364.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


30. Lambrou NC, Gómez-Marín O, Mirhashemi R, Beach H, Salom E, Almeida-Parra Z, Peñalver M: Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol; 2004 Jun;93(3):653-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival.
  • OBJECTIVE: To evaluate the survival impact of residual disease at the time of primary surgery for patients with Stage III and IV endometrial carcinoma; to assess morbidity associated with surgical cytoreduction.
  • METHOD: All patients with endometrial carcinoma who underwent primary surgical therapy at the University of Miami between January 1, 1990 and June 1, 2002 were identified.
  • Patients meeting FIGO criteria for Stage III or IV disease were selected.
  • RESULTS: Eighty-five patients were identified: 66 Stage III and 19 Stage IV.
  • Only Stage IIIC and Stage IV were included in survival analysis: 72% (33 Stage IIIC, 9 Stage IV) had optimal cytoreduction and 28% (6 Stage IIIC, 10 Stage IV) had suboptimal cytoreduction.
  • The median survival for Stage IIIC and IV disease was 6.7 months for patients with suboptimal cytoreduction and 17.8 months for patients with optimal cytoreduction (P = 0.001).
  • CONCLUSIONS: Overall survival is lower and morbidity is higher in patients with advanced endometrial carcinoma having suboptimal cytoreduction at the time of primary surgery.
  • Patients with suspected advanced stage endometrial carcinoma should be counseled on the potential benefits of optimal cytoreductive surgery.
  • Alternative treatment options should be considered in those patients with surgically unresectable disease.
  • [MeSH-major] Endometrial Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / radiotherapy. Carcinoma, Endometrioid / surgery. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Morbidity. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15196860.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Soper JT, Reisinger SA, Ashbury R, Jones E, Clarke-Pearson DL: Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial. Gynecol Oncol; 2004 Oct;95(1):95-100
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial.
  • PURPOSE: A prospective Phase I study to determine toxicity of concurrent weekly intravenous cisplatin/whole abdominopelvic radiation therapy followed by four cycles of intravenous doxorubicin/cisplatin chemotherapy.
  • MATERIALS AND METHODS: Ten patients with advanced endometrial cancer confined to the abdominal cavity and/or paraaortic lymph nodes with small residual disease were treated postoperatively with 3000 cGy whole abdominopelvic irradiation combined with 1500 cGy boost to the pelvis or pelvic and aortic fields.
  • Toxicities were monitored with weekly laboratory studies during treatment and frequent examinations.
  • RESULTS: Five patients with Stage IIIC (paraaortic node involvement) and five with Stage IVB disease were treated on this study.
  • Seven patients received chemotherapy after completing radiation therapy, two progressed before chemotherapy, and one had thrombocytopenia.
  • Toxicity during chemotherapy included grade 4 neutropenia in all patients with four having five episodes of febrile neutropenia.
  • One patient developed a small bowel obstruction from radiation therapy that required surgery.
  • There were no treatment-related deaths.
  • CONCLUSIONS: Without cytokine support, whole abdominopelvic irradiation and concurrent weekly cisplatin followed by doxorubicin/cisplatin chemotherapy without cytokine support has prohibitive hematologic toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Feasibility Studies. Female. Humans. Neoplasm Staging. Pilot Projects. Prospective Studies

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15385116.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


32. Small W Jr, Mahadevan A, Roland P, Vallow L, Zusag T, Fishman D, Massad S, Rademaker A, Kalapurakal JA, Chang S, Lurain J: Whole-abdominal radiation in endometrial carcinoma: an analysis of toxicity, patterns of recurrence, and survival. Cancer J; 2000 Nov-Dec;6(6):394-400

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-abdominal radiation in endometrial carcinoma: an analysis of toxicity, patterns of recurrence, and survival.
  • PURPOSE: The purpose of this study was to determine the toxicity, patterns of recurrence, and survival in high-risk endometrial cancer patients treated with whole-abdominal radiation.
  • MATERIALS AND METHODS: All patients with endometrial cancer treated at Northwestern University since 1994 and at Rush University since 1993 were retrospectively reviewed.
  • Forty-seven percent of the patients were found to have serous histology as a component of their tumor.
  • Surgical staging results included 19% stage 1B, 4% stage IC, 8% stage IIB, 37% stage IIIA, 26% stage IIIC, and 7% stage IVB.
  • Megestrol acetate (Megace) was used as an adjuvant treatment in 37% of patients, and no cases received initial chemotherapy.
  • CONCLUSIONS: Utilizing a conservatrive total whole-abdominal radiation dose and limited para-aortic nodal boost resulted in very tolerable treatments.
  • [MeSH-major] Abdominal Neoplasms / prevention & control. Abdominal Neoplasms / secondary. Endometrial Neoplasms / radiotherapy. Neoplasm, Residual / radiotherapy
  • [MeSH-minor] Adenocarcinoma, Papillary. Brachytherapy. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Ovariectomy. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11131490.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Klopp AH, Jhingran A, Ramondetta L, Lu K, Gershenson DM, Eifel PJ: Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol; 2009 Oct;115(1):6-11
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.
  • OBJECTIVE: To evaluate treatment outcomes and patterns of recurrence in patients with node-positive (International Federation of Obstetrics and Gynecology stage IIIC) adenocarcinoma of the uterus without serous or clear cell differentiation.
  • METHODS: The records of 71 women who were treated for stage IIIC endometrial adenocarcinoma at our institution between 1984 and 2005 were reviewed.
  • Fifty patients received definitive pelvic or extended-field radiotherapy with or without systemic therapy (regional RT group).
  • Eighteen received adjuvant systemic platinum-based chemotherapy or hormonal therapy without external beam RT.
  • Five-year pelvic-relapse-free survival (98% vs 61%, P=0.001), DSS (78% vs 39%, P=0.01), and overall survival (73% vs 40%, P=0.03) were significantly better for the regional RT group than the systemic therapy group.
  • Patients with stage IIIC endometrial adenocarcinoma who underwent surgical staging followed by external beam irradiation had a high rate of cure.
  • Relapses in patients treated with EBRT primarily occurred in patients with grade 3 cancer who may be most likely to benefit from combined-chemoradiation treatment.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Humans. Hysterectomy. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Ovariectomy. Paclitaxel / administration & dosage. Radiotherapy, Adjuvant. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632709.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


34. Aletti GD, Nordquist D, Hartmann L, Gallenberg M, Long HJ, Cliby WA: From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer. Ann Oncol; 2010 Sep;21(9):1772-8
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer.
  • BACKGROUND: The objective of the study was to evaluate completion rates and toxic effects of an i.p. chemotherapy regimen in a cross-section of nonselected patients with ovarian cancer (OC).
  • PATIENTS AND METHODS: All patients with stage IIIC OC consecutively operated at our institution from January 2006 to December 2007 were prospectively collected and analyzed.
  • RESULTS: Eighty-nine patients with stage IIIC OC optimally debulked were evaluated for this study.
  • An i.p. port was primarily placed in 53 of 89 (60%), and i.p. chemotherapy was recommended in 55 patients.
  • Reasons for not recommending i.p. chemotherapy in patients optimally debulked included postoperative complications (n = 7: 8%), poor nutritional/functional status (n = 5: 6%), and extensive surgery including bowel resection (n = 9: 10%).
  • Thirty-three patients (33/55: 60%) recommended to receive i.p. chemotherapy-initiated i.p. treatment.
  • Fifty-two percent of those beginning i.p. therapy (17/33) received three or more cycles with 36% (12/33) successfully completing six cycles.
  • Reasons for discontinuation included grade 3-4 nephrotoxicity in 3 of 21 (14%), febrile neutropenia/sepsis in 3 of 21 (14%), port infection or malfunction in 8 of 21 (38%).
  • CONCLUSIONS: The i.p. chemotherapy regimen used in a consecutive cohort of patients carries could be completed in only a small percentage of patients.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139154.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


35. Dusenbery KE, Potish RA, Gold DG, Boente MP: Utility and limitations of abdominal radiotherapy in the management of endometrial carcinomas. Gynecol Oncol; 2005 Mar;96(3):635-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility and limitations of abdominal radiotherapy in the management of endometrial carcinomas.
  • OBJECTIVE: The present review analyzes long-term survival, recurrence sites, and toxicity in women with peritoneal spread of endometrial treated with abdominal radiotherapy, in order to provide therapeutic options as a function of disease spread and histology.
  • METHODS: Retrospective medical record review was performed of 86 patients receiving abdominal radiotherapy for endometrial carcinomas from 1975 to 1995 at the University of Minnesota.
  • RESULTS: FIGO stage distribution was 54 stage IIIA, 2 stage IIIB, 11 stage IIIC, and 19 stage IVB.
  • Recurrence rates were 16% for stage IIIA with one peritoneal site, 48% for stage IIIA with multiple peritoneal sites or stage IIIB or stage IIIC, and 72% for stage IVB.
  • With univariate analysis, statistical significance was found for stage, gross peritoneal disease, nodal metastases, histology, concurrent chemotherapy, isolated adnexal spread, grade, angiolymphatic invasion, myometrial invasion, and age.
  • Multivariate analysis found only stage, histology, and age to be significant.
  • CONCLUSIONS: Abdominal radiotherapy confers an excellent prognosis for women with stage IIIA cancers with one site of peritoneal involvement.
  • Lack of randomized trials makes definitive treatment recommendations difficult to provide.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / radiotherapy. Peritoneal Neoplasms / radiotherapy. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / radiotherapy. Adenocarcinoma, Papillary / secondary. Adult. Aged. Aged, 80 and over. Cohort Studies. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / radiotherapy. Cystadenocarcinoma, Serous / secondary. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy / adverse effects. Radiotherapy / methods. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721405.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Kelly MG, O'Malley D, Hui P, McAlpine J, Dziura J, Rutherford TJ, Azodi M, Chambers SK, Schwartz PE: Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecol Oncol; 2004 Dec;95(3):469-73
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
  • OBJECTIVE: The coexistence of minimal uterine disease and extrauterine metastases is common in patients with uterine papillary serous carcinoma (UPSC).
  • The purpose of this study was to evaluate different therapeutic options in surgically staged patients.
  • METHODS: We retrospectively reviewed all patients with UPSC histologically limited in the uterus to the endometrium treated at our institution between 1987 and 2002.
  • RESULTS: Twenty-three (45%) cases were International Federation of Gynecology and Obstetrics (FIGO) stage IA, seven (15%) were stage IIIA, one (2%) was stage IIIC, and nine (18%) stage IV.
  • Additionally, 11 of these 51 patients (21%) were diagnosed with two cancers: a stage IA UPSC and concomitant advanced stage serous cancer of the ovary, fallopian tube, or peritoneum.
  • Stage IA patients with no cancer in the hysterectomy specimen (defined as no residual uterine disease) had no recurrences (n = 10) regardless of treatment.
  • There was a trend toward increased survival in stage IA patients with residual uterine disease who were treated with chemoradiation (concomitant vaginal brachytherapy and platinum-based chemotherapy).
  • All patients with advanced stage UPSC (stage IIIC or IV or two primary cancers) did poorly regardless of treatment.
  • CONCLUSION: Our findings suggest that stage IA patients with no residual uterine disease may be observed.
  • Stage IA patients with residual uterine disease may benefit from chemoradiation.
  • More effective treatment needs to be identified for advanced stage UPSC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Papillary / therapy. Cystadenocarcinoma, Serous / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Brachytherapy. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15581948.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin
  •  go-up   go-down


37. Pölcher M, Friedrichs N, Rudlowski C, Fimmers R, Keyver-Paik MD, Kübler K, Sauerwald A, Büttner R, Kuhn W, Braun M: Changes in Ki-67 labeling indices during neoadjuvant chemotherapy for advanced ovarian cancer are associated with survival. Int J Gynecol Cancer; 2010 May;20(4):555-60
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in Ki-67 labeling indices during neoadjuvant chemotherapy for advanced ovarian cancer are associated with survival.
  • OBJECTIVE: To evaluate changes in Ki-67 expression during neoadjuvant chemotherapy (NACT) in advanced ovarian cancer.
  • MATERIALS AND METHODS: Patients with International Federation of Gynecology and Obstetrics stage IIIC or IV and large-volume ascites were treated with NACT within a phase 2 trial.
  • The expression of Ki-67 was evaluated by immunohistochemistry on paraffin-embedded tissue samples and classified by percentage of stained cells.
  • Six of 12 patients with an increased Ki-67 index after NACT developed recurrence within 6 months after therapy.
  • If confirmed in prospective trials, an increasing Ki-67 index during preoperative treatment may serve as an indicator for resistance to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Papillary / drug therapy. Cystadenocarcinoma, Serous / drug therapy. Endometrial Neoplasms / drug therapy. Ki-67 Antigen / metabolism. Neoadjuvant Therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Cell Proliferation. Clinical Trials, Phase II as Topic. Female. Humans. Immunoenzyme Techniques. Middle Aged. Prospective Studies. Randomized Controlled Trials as Topic. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20442588.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


38. Takano M, Yoshikawa T, Kato M, Aida S, Goto T, Furuya K, Kikuchi Y: Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature. Eur J Gynaecol Oncol; 2009;30(5):575-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature.
  • The most common neoplasms of the peritoneum are malignant mesothelioma and serous papillary adenocarcinoma.
  • Clear cell carcinoma (CCC) is mostly derived from the ovary and often associated with endometriosis.
  • Case 1, a 53-year-old woman, presented with upper abdominal and pelvic tumors.
  • Case 2, a 66-year-old woman, presented with massive ascites and abdominal tumor.
  • The ovaries and uterine endometrium of these cases were not affected, and the tumors were diagnosed as Stage IIIc CCC of the peritoneum origin.
  • Pathologically, endometriosis was not observed in either case.
  • Adjuvant chemotherapy using irinotecan and cisplatin was effective in one case.
  • The cases and a review of the literature suggested that residual tumor volume size determines the survival of these patients, and that the tumors show resistance to conventional platinum-based chemotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Antineoplastic Combined Chemotherapy Protocols. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Gynaecol Oncol. 2010;31(1):4. Yoshokawa, T [corrected to Yoshikawa, T]
  • (PMID = 19899421.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 15
  •  go-up   go-down


39. Li B, Wu LY, Zhang WH, Li L, Ma SK, Liu LY: [Clinical analysis of 11 cases of ovarian Setoli-Leydig cell tumor]. Zhonghua Fu Chan Ke Za Zhi; 2004 May;39(5):334-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 11 cases of ovarian Setoli-Leydig cell tumor].
  • OBJECTIVE: To study the clinical characteristics, treatment and prognostic factors of ovarian Setoli-Leydig cell tumor.
  • METHODS: During 1962 - 2002, a total of 11 patients with Setoli-Leydig cell tumor were retrospectively analyzed.
  • RESULTS: Microscopically, seven of the neoplasms were well differentiated, 3 were moderately differentiated and 1 was poorly differentiated.
  • Nine of the tumors were stage Ia, 1 was stage IIc and 1 was stage IIIc.
  • Six patients presented with androgenization and virilization, 3 of which had their serum testosterone tested, and the levels were elevated.
  • In addition, five patients had diseases associated with excessive estrogenic stimulation, such as uterine myoma and endometrial hyperplasia.
  • Two patients suffered from breast cancer.
  • And 5 patients with poorly differentiated or stage II-III tumors were subjected to postoperational chemotherapy.
  • CONCLUSIONS: Ovarian Setoli-Leydig cell tumor has good prognosis.
  • Surgery alone is a currently acceptable treatment for patients with well-differentiated early stage tumors.
  • For patients with poorly differentiated or advanced tumors, postoperational chemotherapy seems to be necessary.
  • Conservative surgery should be the treatment of choice in young patients who need future fertility.
  • [MeSH-major] Ovarian Neoplasms. Sertoli-Leydig Cell Tumor
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15196418.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


40. Tsolakidis D, Amant F, Van Gorp T, Leunen K, Neven P, Vergote I: The role of diaphragmatic surgery during interval debulking after neoadjuvant chemotherapy: an analysis of 74 patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer; 2010 May;20(4):542-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of diaphragmatic surgery during interval debulking after neoadjuvant chemotherapy: an analysis of 74 patients with advanced epithelial ovarian cancer.
  • OBJECTIVES: The purpose of this retrospective study was to evaluate diaphragmatic surgery in achieving optimal cytoreductive results and its associated complications during interval debulking surgery in patients with advanced ovarian cancer.
  • METHODS: After retrospective review of medical records, diaphragmatic surgery was performed in 74 of 128 consecutive patients with advanced epithelial ovarian cancer who underwent interval debulking, between September 1993 and December 2007.
  • RESULTS: Two patients (2.7%) had International Federation of Gynecology and Obstetrics stage IIIB disease; 46 (62.16%), stage IIIC; and 26 (35.13%), stage IV.
  • After 3 to 4 cycles of neoadjuvant platinum-based chemotherapy, the diaphragmatic disease was coagulated in 43 patients (58.10%) and was only stripped in 10 (13.51%); in 19 patients (25.67%), a combination of these techniques was applied; and in 2 (2.70%), the disease was resected, with the adjacent infiltrated part of the diaphragmatic muscle and the pleura above it.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diaphragm / surgery. Neoadjuvant Therapy. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Cystadenocarcinoma, Serous / surgery. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / secondary. Endometrial Neoplasms / surgery. Female. Humans. Medical Records. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686373.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Hiura M, Nogawa T, Matsumoto T, Yokoyama T, Shiroyama Y, Wroblewski J: Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma. Int J Gynecol Cancer; 2010 Aug;20(6):1000-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
  • OBJECTIVE: The purposes of this study were to assess modified radical hysterectomy including systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy in patients with para-aortic lymph node (PAN) metastasis in endometrial carcinoma and to identify the multivariate independent prognostic factors for long-term survival during the past 10 years.
  • METHODS: Between December 1987 and December 2002, we performed modified radical hysterectomy with bilateral salpingo-oophorectomy including systematic pelvic and para-aortic lymphadenectomy and peritoneal cytology in 284 endometrial carcinoma patients according to the classification of the International Federation of Gynecology and Obstetrics (stage IA, n = 66; stage IB, n = 96; stage IC, n = 33; stage IIA, n = 5; stage IIB, n = 20; stage IIIA, n = 28; stage IIIC, n = 28; and stage IV, n = 8) who gave informed consents at our institute.
  • Patients with tumor confined to the uterus (stages IC and II) were treated by 3 courses of cyclophosphamide 750 mg/m2, epirubicin 50 mg/m2, and cisplatin 75 mg/m2 regimen 3 to 4 weeks apart, and patients with extrauterine lesions involving adnexa and/or pelvic lymph node (PLN) were treated by 5 courses.
  • Patients with PLN metastasis received adjuvant chemotherapy, and adjuvant radiation was not part of our institutional protocol.
  • RESULTS: The overall incidence of retroperitoneal lymph node metastasis assessed by systematic pelvic and para-aortic lymphadenectomy was 12.0% (34/284) in stages I to IV endometrial carcinoma, and incidences of PLN and PAN metastases were 9.2% (26/284) and 7.4% (21/284), respectively.
  • Univariate analysis of prognostic factors revealed that International Federation of Gynecology and Obstetrics clinical stage (P < 0.0001), histological finding (P = 0.0292), myometrial invasion (P < 0.0001), adnexal metastasis (P < 0.0001), lymphovascular space invasion (P < 0.0001), tumor diameter (P = 0.0108), peritoneal cytology (P = 0.0001), and retroperitoneal lymph node metastasis (P < 0.0001) were significantly associated with 10-year overall survival.
  • CONCLUSIONS: It is suggested that surgery with systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy could improve long-term survival in patients with PAN metastasis, although there are only 21 patients with PAN metastasis.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / secondary. Chemotherapy, Adjuvant. Endometrial Neoplasms / mortality. Endometrial Neoplasms / therapy. Retroperitoneal Neoplasms / secondary. Retroperitoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Aorta, Abdominal. Biopsy, Needle. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Lymph Node Excision / methods. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Retroperitoneal Space. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683408.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, Roche M, Colella T, Lee H, Seiden MV, Gynecologic Oncology Research Program at Dana Farber/Partners Cancer Care, Dana Farber-Harvard Cancer Care: A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecol Oncol; 2003 Nov;91(2):293-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
  • OBJECTIVES: In an effort to improve the results of primary chemotherapy for müllerian malignancies a novel chemotherapy program was piloted that delivered three sequential chemotherapy doublets.
  • After therapy, all women were clinically staged and evaluated by second-look laparoscopy/laparotomy (SLO) if clinical staging was negative for residual disease.
  • Forty-four women had either ovarian cancer or primary peritoneal carcinoma with 3 women diagnosed with fallopian tube carcinoma and 2 with papillary serous carcinoma of the uterus.
  • Eighty-four percent of patients had stage IIIc/IV tumors, with 29% having >1 cm residual disease after primary cytoreductive surgery.
  • Thirty-nine of 49 (80%) patients completed therapy.
  • A total of 283 cycles of chemotherapy were delivered with acceptable toxicities.
  • Five women were withdrawn from trial (3 for Taxol hypersensitivity, 1 for gemcitabine pulmonary hypersensitivity, and 1 for serious line infection).
  • Thirty-nine women completed all cycles of treatment.
  • CONCLUSIONS: Treatment with this sequential doublet regimen is feasible with a 38% pathologic CR rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Deoxycytidine / analogs & derivatives. Genital Neoplasms, Female / drug therapy. Mixed Tumor, Mullerian / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Carboplatin / adverse effects. Combined Modality Therapy. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / surgery. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Middle Aged. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery. Topotecan / administration & dosage. Topotecan / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599858.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


43. Ashman JB, Connell PP, Yamada D, Rotmensch J, Waggoner SE, Mundt AJ: Outcome of endometrial carcinoma patients with involvement of the uterine serosa. Gynecol Oncol; 2001 Aug;82(2):338-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of endometrial carcinoma patients with involvement of the uterine serosa.
  • OBJECTIVE: The goal of this work was to evaluate the outcome of endometrial carcinoma patients undergoing primary surgery who have serosal involvement (SI).
  • METHODS: Between 1980 and 1998, 562 women underwent primary surgery for endometrial cancer at the University of Chicago.
  • FIGO stages were IIIA (19), IIIB (1), IIIC (7), and IV (12).
  • Twenty-six patients received pelvic radiation therapy (RT) with or without vaginal brachytherapy (VB).
  • One patient received whole-abdomen radiation therapy, and 13, adjuvant chemotherapy.
  • Solitary SI patients received pelvic RT with or without VB as their sole adjuvant therapy.
  • Factors correlated with disease recurrence included tumor stage (P = 0.003) and lymph node involvement (P = 0.04).
  • CONCLUSION: Endometrial carcinoma patients with SI have a high rate of relapse and a poor outcome.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11531290.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / 5 T32 GM07281
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


44. Bakrin N, Cotte E, Sayag-Beaujard A, Raudrant D, Isaac S, Mohamed F, Gilly FN, Glehen O: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of recurrent endometrial carcinoma confined to the peritoneal cavity. Int J Gynecol Cancer; 2010 Jul;20(5):809-14
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of recurrent endometrial carcinoma confined to the peritoneal cavity.
  • Our objective was to determine if cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a feasible therapeutic option for treatment of peritoneal recurrence of endometrial carcinoma.
  • Between August 2002 and May 2007, 5 patients with recurrent endometrial carcinoma confined to the peritoneal cavity who underwent CRS with HIPEC.
  • Of the 5 patients treated, histopathological type and International Federation of Gynecology and Obstetrics stage were as follows: IB endometrioid (n = 1), IIIA endometrioid (n = 1), IIIC endometrioid (n = 2), and IC endometrioid + pseudosarcomatoid component (n = 1).
  • One patient with pseudosarcomatoid component developed recurrent disease 10 months after surgery and died 2 months later.
  • One patient experienced early recurrence with a malignant pleural effusion and died.
  • Regarding the toxicity of the procedure, highly selected patients with recurrent endometrial carcinoma confined to the peritoneal cavity may benefit from improved survival after CRS with HIPEC.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Endometrial Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Gynecologic Surgical Procedures. Humans. Hyperthermia, Induced. Infusions, Parenteral. Middle Aged. Mitomycin / administration & dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973274.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


45. Eltabbakh GH, Shamonki J, Mount SL: Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors. Gynecol Oncol; 2005 Nov;99(2):309-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors.
  • OBJECTIVE: The purpose of our study was to assess the surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy showed well-differentiated (FIGO grade 1) carcinoma.
  • MATERIALS AND METHODS: A retrospective study was conducted including all women treated at the University of Vermont between 1992 and 2004 whose preoperative endometrial biopsy was reviewed by the staff at the Pathology Department and diagnosed as FIGO grade 1 adenocarcinoma and who received peritoneal washings, total abdominal (or laparoscopic) hysterectomy, bilateral salpingo-oophorectomy, and pelvic +/- para-aortic lymphadenectomy as part of their surgery.
  • The surgical stages were: IA: 55 (30.2%), IB: 61 (33.5%), IC: 26 (14.3%), IIA: 9 (4.9%), IIB: 8 (4.4%), IIIA: 10 (5.5%), IIIB: 2 (1.1%), IIIC: 8 (4.4%), and IV: 3 (1.6%).
  • Postoperatively, 131 (72%) patients received no additional treatment, 47 (25.8%) received radiation therapy, 3 (1.6%) received chemotherapy, and 1 (0.5%) received Megace.
  • CONCLUSIONS: Approximately 30% of women with endometrial carcinoma whose preoperative endometrial biopsy shows grade 1 tumors have grade 2 or 3 in the hysterectomy specimen and 12.6% have advanced surgical stage (stage III and IV) disease.
  • Women with preoperative endometrial biopsy showing grade 1 tumors who undergo surgical staging have excellent survival and acceptable operative morbidity.
  • [MeSH-major] Endometrial Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cell Differentiation / physiology. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16005945.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Murphy KT, Rotmensch J, Yamada SD, Mundt AJ: Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys; 2003 Apr 1;55(5):1272-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
  • PURPOSE: To evaluate the outcome and patterns of failure in women with uterine clear-cell carcinoma and discuss implications for adjuvant radiation therapy (RT).
  • METHODS: Between 1980 and 2000, 686 endometrial carcinoma patients underwent primary surgery at our institution.
  • Thirty-eight women (5.5%) had clear-cell tumors (18 clear-cell only, 8 clear-cell + adenocarcinoma, and 12 clear-cell + other unfavorable histologies [10 papillary serous, 1 uterine sarcoma, 1 both]).
  • FIGO stages were as follows: 3 IA, 4 IB, 5 IC, 4 IIA, 6 IIB, 8 IIIA, 2 IIIB, 3 IIIC, and 6 IV.
  • Adjuvant therapies included the following: 5 none, 22 RT (13 pelvic RT, 2 vaginal brachytherapy, 7 both), 11 chemotherapy (8 alone, 3 after pelvic RT), and 3 hormones.
  • No correlation was seen between relapse and stage, myometrial invasion, cytology, cervical extension, or involvement of extrauterine sites.
  • Corresponding pelvic failure rates in the Stage IA-IIB patients with and without RT were 0/16 (0%) and 5/6 (83%) (p < 0.0001).
  • Only 1 (2%) patient developed an isolated abdominal failure (This patient had a mixed clear-cell/papillary serous tumor).
  • CONCLUSION: Clear-cell carcinoma comprises a small percentage of endometrial cancers, frequently presents as a mixed histology, and has a poor overall outcome.
  • Unlike papillary serous tumors, clear-cell carcinoma does not seem to have a high propensity for abdominal failure.
  • Future protocols should focus instead on combinations of locoregional RT and chemotherapy to reduce the risk of local and systemic recurrence.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometrial Neoplasms / pathology. Radiotherapy, Adjuvant
  • [MeSH-minor] Abdominal Neoplasms / secondary. Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Brachytherapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cystadenocarcinoma / pathology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy. Life Tables. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / mortality. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Pelvic Neoplasms / secondary. Prognosis. Sarcoma / pathology. Treatment Failure. Treatment Outcome. Uterine Neoplasms / pathology. Vaginal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12654437.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 30
  •  go-up   go-down


47. Eltabbakh GH, Mount SL: Laparoscopic surgery does not increase the positive peritoneal cytology among women with endometrial carcinoma. Gynecol Oncol; 2006 Feb;100(2):361-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic surgery does not increase the positive peritoneal cytology among women with endometrial carcinoma.
  • OBJECTIVE: The purpose of our study was to find if uterine manipulation at the time of laparoscopic hysterectomy among women with endometrial carcinoma increases the incidence of malignant cells in the peritoneal washings.
  • MATERIAL AND METHODS: We conducted a prospective study including women with clinical stage I endometrioid endometrial carcinoma undergoing laparoscopic surgery between 07/01/2000 and 07/01/2004.
  • Two sets of peritoneal washings were obtained, one before and one after the insertion of the Pelosi uterine manipulator.
  • The two sets of washings were blindly reviewed by the same cytopathologist for the presence of malignant cells.
  • The procedure was converted to laparotomy in 3 (7.6%) patients after obtaining the two sets of washings.
  • The preoperative tumor grades were: G1: 22 (52.4%), G2: 12 (28.6%), and G3: 8 (19.0).
  • No patients had positive washings after the insertion of the uterine manipulator if the washings were negative before the insertion.
  • The surgical stages were: IA: 14 (33.3%), IB: 12 (28.6%), IC: 7 (16.7%), IIA: 1 (2.4%), IIB: 1 (2.4%), IIIA: 4 (9.5%), IIIB: 1 (2.4%), IIIC: 1 (2.4%), and IV: 1 (2.4%).
  • Twenty-nine patients received no postoperative treatment, 2 received chemotherapy, 3 received Megace, and 9 received radiation therapy.
  • Two patients had tumor recurrence, and one patient died secondary to her disease.
  • CONCLUSIONS: We conclude that uterine manipulation at the time of laparoscopic hysterectomy does not increase the incidence of positive peritoneal cytology among women with endometrial carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Neoplasm Seeding. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185754.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement